Oncodrex

Oncodrex is a private Canadian oncology company developing both targeted therapeutics and cancer diagnostics. The company says it uses proprietary molecular signatures to identify drug targets and biomarker-driven patient-selection strategies. Its disclosed therapeutic focus is on small-molecule candidates for hard-to-treat metastatic cancers, particularly triple-negative breast cancer, alongside a companion diagnostic for responder selection. Oncodrex has also described a blood-based test for early detection and screening of colorectal cancer. Overall, the company appears to operate as an early-stage precision-oncology platform spanning biomarker discovery, diagnostics, and preclinical drug development.